Explaining blood pressure reduction heterogeneity in sodium-glucose cotransporter-2 inhibitor trials: a meta-analysis stratified by patient characteristics.
Josef Toma Alyas, Steffen Flindt Nielsen, Niels Henrik Buus
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis assessed the blood pressure-lowering effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) across 38 randomized controlled trials involving 48,828 patients. It found that in individuals with type 2 diabetes (T2DM), systolic blood pressure (SBP) decreased by -3.66 mmHg, while those without T2DM experienced a reduction of -1.79 mmHg. The analysis highlighted that the effects were most significant in T2DM populations.
Key findings
- In patients with T2DM, SBP decreased by -3.66 mmHg (95% CI: -4.16, -3.16).
- Patients without T2DM showed a significant SBP reduction of -1.79 mmHg (95% CI: -2.85, -0.72).
- The Robust Bayesian Meta-analysis indicated most results were clinically trivial (<2 mmHg) except in T2DM populations.
- Meta-regression identified T2DM and 24-h BP measurement as significant moderators for greater SBP reduction.
Why it matters
Understanding the differential effects of SGLT-2 inhibitors on blood pressure in various patient populations can guide clinicians in optimizing treatment strategies for hypertension, particularly in those with type 2 diabetes.